Inhibitors of the Bacterioferritin Ferredoxin Complex Dysregulate Iron Homeostasis and Kill Acinetobacter baumannii and Biofilm-Embedded Pseudomonas aeruginosa Cells.
Alexanndra M Behm, Huili Yao, Emmanuel C Eze, Suliat A Alli, Simon D P Baugh, Ebenezer Ametsetor, Kendall M Powell, Kevin P Battaile, Steve Seibold, Scott Lovell, Richard A Bunce, Allen B Reitz, Mario Rivera
{"title":"Inhibitors of the Bacterioferritin Ferredoxin Complex Dysregulate Iron Homeostasis and Kill <i>Acinetobacter baumannii</i> and Biofilm-Embedded <i>Pseudomonas aeruginosa</i> Cells.","authors":"Alexanndra M Behm, Huili Yao, Emmanuel C Eze, Suliat A Alli, Simon D P Baugh, Ebenezer Ametsetor, Kendall M Powell, Kevin P Battaile, Steve Seibold, Scott Lovell, Richard A Bunce, Allen B Reitz, Mario Rivera","doi":"10.1021/acsinfecdis.5c00209","DOIUrl":null,"url":null,"abstract":"<p><p>In <i>Pseudomonas aeruginosa</i>, the iron storage protein bacterioferritin (Bfr) contributes to buffering cytosolic free iron concentrations by oxidizing Fe<sup>2+</sup> and storing the resultant Fe<sup>3+</sup> in its internal cavity, and by forming a complex with a cognate ferredoxin (Bfd) to reduce the stored Fe<sup>3+</sup> and mobilize Fe<sup>2+</sup> to the cytosol. Small molecule derivatives of 4-aminoisoindoline-1,3-dione designed to bind <i>P. aeruginosa</i> Bfr (Pa Bfr) at the Bfd binding site accumulate in the <i>P. aeruginosa</i> cell, block the Pa Bfr-Bfd complex, inhibit iron mobilization from Pa Bfr, elicit an iron starvation response, are bacteriostatic to planktonic cells, and are bactericidal to biofilm-entrenched cells. A structural alignment of Pa Bfr and <i>Acinetobacter baumannii</i> Bfr (Ab Bfr) showed strong conservation of the Bfd binding site on Ab Bfr. Accordingly, the small molecule inhibitors of the Pa Bfr-Bfd complex accumulate in the <i>A. baumannii</i> cells, elicit an iron starvation response, are bactericidal to planktonic cells, and exhibit synergy with existing antibiotics. These findings indicate that the inhibition of iron mobilization from Bfr may be an antimicrobial strategy applicable to other Gram-negative pathogens.</p>","PeriodicalId":17,"journal":{"name":"ACS Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":4.0000,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acsinfecdis.5c00209","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
In Pseudomonas aeruginosa, the iron storage protein bacterioferritin (Bfr) contributes to buffering cytosolic free iron concentrations by oxidizing Fe2+ and storing the resultant Fe3+ in its internal cavity, and by forming a complex with a cognate ferredoxin (Bfd) to reduce the stored Fe3+ and mobilize Fe2+ to the cytosol. Small molecule derivatives of 4-aminoisoindoline-1,3-dione designed to bind P. aeruginosa Bfr (Pa Bfr) at the Bfd binding site accumulate in the P. aeruginosa cell, block the Pa Bfr-Bfd complex, inhibit iron mobilization from Pa Bfr, elicit an iron starvation response, are bacteriostatic to planktonic cells, and are bactericidal to biofilm-entrenched cells. A structural alignment of Pa Bfr and Acinetobacter baumannii Bfr (Ab Bfr) showed strong conservation of the Bfd binding site on Ab Bfr. Accordingly, the small molecule inhibitors of the Pa Bfr-Bfd complex accumulate in the A. baumannii cells, elicit an iron starvation response, are bactericidal to planktonic cells, and exhibit synergy with existing antibiotics. These findings indicate that the inhibition of iron mobilization from Bfr may be an antimicrobial strategy applicable to other Gram-negative pathogens.
期刊介绍:
ACS Infectious Diseases will be the first journal to highlight chemistry and its role in this multidisciplinary and collaborative research area. The journal will cover a diverse array of topics including, but not limited to:
* Discovery and development of new antimicrobial agents — identified through target- or phenotypic-based approaches as well as compounds that induce synergy with antimicrobials.
* Characterization and validation of drug target or pathways — use of single target and genome-wide knockdown and knockouts, biochemical studies, structural biology, new technologies to facilitate characterization and prioritization of potential drug targets.
* Mechanism of drug resistance — fundamental research that advances our understanding of resistance; strategies to prevent resistance.
* Mechanisms of action — use of genetic, metabolomic, and activity- and affinity-based protein profiling to elucidate the mechanism of action of clinical and experimental antimicrobial agents.
* Host-pathogen interactions — tools for studying host-pathogen interactions, cellular biochemistry of hosts and pathogens, and molecular interactions of pathogens with host microbiota.
* Small molecule vaccine adjuvants for infectious disease.
* Viral and bacterial biochemistry and molecular biology.